A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAY x 3702) in ischemic stroke

CNS Drug Reviews

Volumn 11, Issue 4, 2005, Pages 379-402

  Berends, A C ^a   Luiten, Paul G M ^a,b   Nyakas, C ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Apoptosis; BAY x 3702; Excitotoxicity; Ischemia; Neuroprotection; Repinotan HCL; Stroke

Indexed keywords

CASPASE 3; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; IDAZOXAN; INWARDLY RECTIFYING POTASSIUM CHANNEL; MITOGEN ACTIVATED PROTEIN KINASE; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NERVE GROWTH FACTOR; NEURITE PROMOTING FACTOR; PLACEBO; PRAZOSIN; PROTEIN BCL 2; PROTEIN KINASE C ALPHA; PROTEIN S100B; RACLOPRIDE; REPINOTAN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR;

ABSENCE OF SIDE EFFECTS; ANIMAL MODEL; BRAIN BLOOD FLOW; BRAIN DAMAGE; BRAIN INFARCTION SIZE; BRAIN INJURY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG URINE LEVEL; GENOTOXICITY; HUMAN; HYPERPOLARIZATION; IN VIVO STUDY; NERVE EXCITABILITY; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOGENESIS; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC MEMBRANE; REVIEW; TOXICITY TESTING;

EID: 33646578468     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2005.tb00055.x     Document Type: Review

References (148)

1. Adayev T, El-Sherif Y, Barua M, Penington NJ, Banerjee P. Agonist stimulation of the serotonin 1A receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN-2-5 cells. J Neurochem 1999;72:1489-1496.
2. 1A receptor causes suppression of caspase-3 through MAPK and protein kinase Cα. Biochim Biophys Acta 2003;1640:85-96.
3. 1A-receptor agonist, Bay x 3702. Brain Res 2000;858:121-128.
4. 1A receptor agonist, Bay x 3702, inhibits apoptosis induced by serum deprivation in cultured neurons. Eur J Pharmacol 1999;370:211-216.
5. 1A inhibits apoptosis induced by serum deprivation in cultured neurons from chick embryo. Brain Res 1997;777:179-186.
6. Alessandri B, Tsuchida E, Bullock RM. The neuroprotective effect of a new serotonin receptor agonist, BAY x 3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat. Brain Res 1999;845:232-235.
7. 1A receptors in the rat hippocampus and cortex. Drug Dev Res 1992;26:275-286.
8. Azmitia EC. Modern views on an ancient chemical: Serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res Bull 2001;56:413-424.
9. Azmitia EC, Dolan K, Whitaker-Azmitia PM. S-100β but not NGF, EGF, insulin, or calmodulin is a serotonergic growth factor. Brain Res 1990;516:354-356.
10. 1A agonist and dexamethasone reversal of PCA-induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain. Brain Res 1995;677:181-185.
11. Azmitia EC, Whitaker-Azmitia PM. Awakening the sleeping giant: Anatomy and plasticity of the brain serotonergic system. J Clin Psychiatry 1991;52:4-16.
12. Baker AJ, Zornow MH, Scheller MS, et al. Changes in extracellular concentrations of glutamate, aspartate, glycine, dopamine, serotonin, and dopamine metabolites after transient global ischemia in the rabbit brain. J Neurochem 1991;57:1370-1379.
13. Barger SW, Van Eldik LJ, Mattson M. S-100β protects hippocampal neurons from damage induced by glucose deprivation. Brain Res 1995;677:167-170.
14. Benyo Z, De Jong GI, Luiten PGM. Nimodipine prevents early loss of hippocampal CA1 parvalbumin immunoreactivity after focal cerebral ischemia in the rat. Brain Res Bull 1995;36:569-572.
15. Bielenberg GW, Burkhart M. 5-hydroxytryptamine 1A agonists. A new therapeutic principle for stroke treatment. Stroke 1990;21(Suppl IV):161-163.
16. Bode-Greuel KM, Klisch J, Horvath E, Glaser T, Traber J. Effects of 5-hydroxytryptamine 1A receptor agonists on hippocampal damage after transient forebrain ischemia in Mongolian gerbil. Stroke 1990;21:164-166.
17. 2A receptors: Effect of antipsychotic drugs. Eur J Neurosci 2003;18:1235-1246.
18. Boxer PA, Bigge CF. Mechanisms of neuronal cell injury/death and targets for drug intervention. Drug Discov Today 2 1997;2:219-228.
19. 1A receptors to N- and L-type calcium channels in C-like rat dorsal root ganglion cells. J Neurophysiol 1997;77:3284-3296.
20. Casanovas JM, Artigas F. Differential effects of ipsapirone on 5-HT release in the dorsal and median raphe neuronal pathways. J Neurochem 1996;67:1945-1952.
21. 1A receptor agonist BAY x 3702 on serotonergic cell firing and release. Arch Pharmacol 2000;362:248-254.
22. 1A receptors control 5-HT release in the rat medial prefrontal cortex. Neuroreport 1999;10:1441-1445.
23. 1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain. Br J Pharmacol 1997;122:733-741.
24. 1A binding in rat brain - a combined in situ hybridisation/in vitro receptor autoradiographic study. Brain Res 1991;561:51-60.
25. Chaput Y, de Montigny C. Effects of the 5-hydroxytryptamine1 receptor antagonist, BMY 7378, on 5-hydroxytryptamine1 neurotransmission: Electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther 1988;246:359-370.
26. Chen J, Simon RP, Nagayama T, et al. Suppression of endogenous bcl-2 expression by antisense treatment exacerbates ischemic neuronal death. J Cereb Blood Flow Metab 2000;20:1033-1039.
27. Choi DW. Cellular defences destroyed. Nature 2005;433:696-698.
28. Clark RS, Kochanek PM, Marion DW, et al. Mild posttraumatic hypothermia reduces mortality after severe controlled cortical impact in rats. J Cereb Blood Flow Metab 1996;16:253-261.
29. 1A receptor-mediated ERK activation requires calcium/calmodulin- dependent receptor endocytosis. J Biol Chem 1999;274:4749-4753.
30. De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing? Trends Neurosci 1999;22:535-540.
31. 1A receptor agonists: Recent developments and controversial issues. Psychopharmacology 1995;121:1-26.
32. 1A receptors in psychopathology and the mechanism of action of clinically effective therapeutic agents. Drug News Perspect 1996;9:270-280.
33. 1A agonist. Drugs Future 1997;22:341-349.
34. 1A receptor agonist BAY x 3702 in the rat. Eur J Pharmacol 1998;357:1-8.
35. 1A receptor agonist properties. Soc Neurosci 1997;23:1922 (Abstract 745.6).
36. De Vry J, Schohe-loop R, Heine HG, et al. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5- hydroxytryptamine(1A) receptor agonist. J Pharmacol Exp Ther 1998;284:1082-1094.
37. 1A receptors electrophysiological studies in the rat hippocampus and dorsal raphe. J Pharmacol Exp Ther 1998;286:1239-1247.
38. Doppenberg EMR, Bullock R. Clinical neuro-protection trials in severe traumatic brain injury: Lessons from previous studies. J Neurotrauma 1997;14:71-80.
39. 1A receptors: Electrophysiological studies in the rat hippocampus and dorsal raphe. J Pharmacol Exp Ther 1998;286:1239-1247.
40. Dunn LT. Head injury therapies. Exp Opin Invest Drugs 1997;6:1511-1526.
41. Fanburg BL, Lee SL. A new role for an old molecule: Serotonin as a mitogen. Am J Physiol 1997;27: L795-L806.
42. Fanò G, Biocca S, Fulle S, Mariggiò MA, Belia S, Calissano P. A protein family in search of a function. Prog Neurobiol 1995;46:71-82.
43. 1A receptor antagonist, WAY 100635. Eur J Pharmacol 1995;281:81-88.
44. Fulle S, Mariggiò MA, Belia S, Nicoletti I, Fanò G. Nerve growth factor inhibits apoptosis induced by S-100 binding in neuronal PC12 cells. Neuroscience 1997;76:159-166.
45. 1A receptor involves distinct signalling cascades. Biochem J 1998;330:489-495.
46. Gerlach I, Horvath E, Jork R. BAY x 3702 ameliorates sensorimotor performance after subdural hematoma. J Neurotrauma 1998;15:870.
47. Gerlai R, Wojtowicz JM, Marks A, Roder J. Overexpression of a calcium binding protein, S-100b, in astrocytes impairs synaptic plasticity and spatial learning in transgenic mice. Learn Mem 1995;2:26-31.
48. Gillardon F, Lenz C, Waschke KF, et al. Altered expression of Bcl-2, Bcl-X, Bax, and c-Fos co-localises with DNA fragmentation and ischemic cell damage following middle cerebral artery occlusion in rats. Mol Brain Res 1996;40:254-260.
49. Green DR. Apoptotic pathways: The roads to ruin. Cell 1998;94:695-698.
50. 1A receptors. J Neurosci 1998;18:10150-10156.
51. Hansra G, Garcia-Paramio P, Prevostel C, Whelan RDH, Bornancin F, Parker P. Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes. Biochem J 1999;342:337-344.
52. Haring JH, Hagan A, Olson J, Rodgers B. Hippocampal serotonin levels influence the expression of S-100β detected by immunocyto-chemistry. Brain Res 1993;631:119-123.
53. 2+ antagonist nimodipine. Neuroscience 2000;101:97-110.
54. Harkany T, Grosche J, Mulder J, et al. Short-term consequences of N-methyl-D-aspartate excitotoxicity in rat magnocellular nucleus basalis: Effects on in vivo labelling of cholinergic neurons. Neuroscience 2001;108:611-627.
55. 1A receptor agonist Repinotan hydrochloride (BAY x 3702) attenuates NMDA-induced delayed neuronal death in rat magnocellular nucleus basalis. Neuroscience 2001;108:629-642.
56. Herrmann M, Curio N, Jost S, Wunderlich MT, Synowitz H, Wallesch CW. Protein S-100β and neuron-specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. Restor Neurol Neurosci 1999;14:2-3.
57. Hjorth S. Hypothermia in the rat induced by the potent serotonergic agent 8-OH-DPAT. J Neural Transm 1985;61:131-135.
58. Holmin S, Mathiesen T, Shetye J, Biberfeld P. Intracerebral inflammatory response to experimental brain confusion. Acta Neurochir 1995;132:110-119.
59. Horiuchi M, Akishita M, Dzau VJ. Molecular and cellular mechanism of angiotensin II-mediated apoptosis. Endocrinol Res 1998;24:307-314.
60. Hortelano S, Bosca LA. 6-Mercaptopurine decreases the bcl-2/bax ratio and induces apoptosis in activated splenic B-lymphocytes. Mol Pharmacol 1997;51:414-421.
61. 1A receptor agonist BAY x 3702 in the rat model of acute subdural hematoma. J Neurotrauma 1997;14:800(Abstract 170).
62. 1A receptor agonist BAY x 3702 in rat model of permanent focal cerebral ischemia and traumatic brain injury. Soc Neurosci Abstr 1997;23:1923(Abstract 745.9).
63. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994;46:157-203.
64. Isenmann S, Stoll G, Schroeter M, Krajewski S, Reed JC, Bahr M. Differential regulation of Bax, Bcl-2 and Bcl-X proteins in focal cortical ischemia in the rat. Brain Pathol 1998;8:49-62.
65. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;14:1255-1259.
66. Jennett B, Frankowski RF. The epidemiology of head injury. In: Handbook of clinical neurology, Braakman R, Ed. New York: Elsevier, 1990:1-16.
67. 2+ channel blocker, in a focal ischemic model in the rat. Brain Res 2003;969:168-174.
68. Khateb A, Fort P, Alonso A, Jones BE, Muhlethaler M. Pharmacological and immunohistochemical evidence for serotonergic modulation of cholinergic nucleus basalis neurons. Eur J Neurosci 1993;5:541-547.
69. 1A receptor antagonist, to rat brain. J Neurochem 1995;64:2716-2726.
70. Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6, transforming growth factor-β, and S-100 protein in patients with acute stroke. Stroke 1996;27:1553-1557.
71. 1A receptor agonist repinotan HCL attenuates histopathology and spatial learning deficits following traumatic brain injury in rats. Neuroscience 2001;106:547-555.
72. Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997;41:135-144.
73. 1A receptor-mediated pathways by BAY x 3702 in freely moving rats. Neurosci Lett 1999;265:33-36.
74. Kozuka M, Itawa N. Changes in levels of monoamines and their metabolites in incompletely ischemic brains of spontaneously hypertensive rats. Neurochem Res 1995;20:1429-1435.
75. Kukley M, Schaper C, Becker A, Rose K, Krieglstein J. Effect of 5-hydroxytryptamine 1A receptor agonist BAY X 3702 on BCL-2 and BAX proteins level in the ipsilateral cerebral cortex of rats after transient focal ischaemia. Neuroscience 2001;107:405-413.
76. Kuroiwa T, Ting P, Martinez H, Klatzo I. The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol 1985;68:122-129.
77. 1A receptor antagonists. Eur J Pharmacol 1998;346:209-215.
78. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997;49(Suppl 4):S66-S69.
79. Lewén A, Fredriksson A, Li GL, Olsson Y, Hillered L. Behavioural and morphological outcome of mild cortical contusion trauma of the rat brain: Influence of NMDA-receptor blockade. Acta Neurochir 1999;141:193-202.
80. Lewis D, Teyler TJ. Anti-S-100 serum blocks long-term potentiation in the hippocampal slice. Brain Res 1986;38:159-166.
81. Linnik MD. Programmed cell death in cerebral ischemia: Therapeutic implication. CNS Drugs 1995;3:239-244.
82. Linnik MD, Zobrist RH, Hatfield MD. Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats. Stroke 1993;24:2002-2008.
83. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79:1431-1568.
84. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622.
85. Liu YZ, Boxer LM, Latchman DS. Activation of Bcl-2 promoter by nerve growth factor is mediated by the p42/p44 MAPK cascade. Nucleic Acids Res 1999;27:2086-2090.
86. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003;4:399-415.
87. Lo EH, Pan Y, Matsumoto K, Kowall NW. Blood-brain barrier disruption in experimental focal ischemia: Comparison between in vivo MRI and immunocytochemistry. Magn Res Imaging 1994;12:403-411.
88. Lotem J, Cragoe EJ, Sachs L. Rescue from programmed cell death in leukemic and normal myeloid cells. Blood 1991;78:953-960.
89. Lu B, Yokoyama M, Dreyfus C, Black IB. Depolarizing stimuli regulate nerve growth factor gene expression in cultured hippocampal neurons. Proc Natl Acad Sci USA 1991;88:6289-6292.
90. 2+ antagonist nimodipine, influence of aging and developmental drug treatment. Neurodegeneration 1995;4:307-314.
91. MacManus JP, Buchan AM, Hill IE, Rasquinha I, Preston E. Global ischemia can cause DNA fragmentation indicative of apoptosis in rat brain. Neurosci Lett 1993;164:89-92.
92. 1A receptor agonist with neuroprotective properties. Soc Neurosci Abstr 1997;23:1923 (Abstract 745.8)
93. Marion DW, Penrod LE, Kelsey SF, et al. Treatment of traumatic brain injury with moderate hypothermia. N Engl J Med 1997;336:540-546.
94. 2+ homeostasis pathways, cell death and protection after oxygen-glucose-deprivation in organotypic hippocampal slice cultures. Neuroscience 2004;128:729-740.
95. 1A receptors in guinea pig dentate gyrus. Brain Res 1996;728:175-180.
96. 1A receptor agonist BAY x 702 in vitro and in vivo. Brain Res 2001;888:150-157.
97. 1A receptor agonist, in animal models of stroke and traumatic brain injury. J Cereb Blood Flow Metab 2005;25:451-459.
98. 1A receptor agonist 8-OH-DPAT: Possible significance for neuroprotection. Eur J Pharmacol 2000;406:319-324.
99. Millan MJ, Rivet JM, Canton H, Le Maouille-Girardon S, Gobert A. Induction of hypothermia as a model of 5-hydroxytryptamine 1A receptor-mediated activity in the rat: A pharmacological characterization of the actions of novel agonists and antagonists. J Pharmacol Exp Ther 1993;264:1364-1376.
100. Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron specific enolase concentration in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997;28:1956-1960.
101. Mocchetti I, Bernardi MA, Szekeley AM, Alho H, Brooker G, Costa E. Regulation of nerve growth factor biosynthesis by β-adrenergic receptor activation in astrocytoma cells: A potential role of c-fos protein. Proc Natl Acad Sci USA 1989;86:3891-3895.
102. Mohr JP, Gautier JC, Hier D, Stein RW. Middle cerebral artery. In: Stroke: Pathophysiology, diagnosis and management. Vol. 1, Barnett HJM, Stein BM, Mohr JP, Yatsu FM, Eds. New York: Churchill Livingstone, 1986;377-450.
103. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965;19:739-744.
104. Mukhin YV, Garnovskaya MN, Collinsworth G, et al. R-hydroxytryptamine 1A receptor/Gi β γ stimulates mitogen-activated protein kinase via NAD(P)H oxidase and reactive oxygen species upstream of src in Chinese hamster ovary fibroblasts. Biochem J 2000;347:61-67.
105. Nakata N, Suda H, Izumi J, et al. Role of hippocampal serotoninergic neurones in ischemic neuronal death. Behav Brain Res 1997;83:217-220.
106. 1A receptor binding sites in rat cortex, hippocampus and cholinergic basal forebrain nuclei during aging. J Chem Neuroanat 1997;13:53-61.
107. 1A agonist in traumatically brain injured patients. J Neurotrauma 2001;18:1313-1321.
108. Okiyama K, Smith DH, White WF, Richter K, McIntosh TK. Effects of the novel NMDA antagonists CP-98,113, CP-101,581, and CP-101-606 on cognitive function and regional cerebral edema following experimental brain injury in the rat. J Neurotrauma 1997;14:211-222.
109. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360-1362.
110. + channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemia. Brain Res 2001;888:138-149.
111. Osborne KA, Shigeno T, Balarsky AM, et al. Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia. J Neurol Neurosurg Psychiatry 1987;50:402-410.
112. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: An update. Drug News Perspect 1998;11:523-569.
113. Phillips LL, Lyeth BG, Hamm RJ, Jiang JY, Povlishock JT, Reeves TM. Effect of prior receptor antagonism on behavioural morbidity produced by combined fluid percussion injury and entorhinal cortical lesion. J Neurosci Res 1997;49:197-206.
114. Phillips LL, Lyeth BG, Hamm RJ, Reeves TM, Povlishock JT. Glutamate antagonism during secondary deafferentation enhances cognitive and axo-dendritic integrity after traumatic brain injury. Hippocampus 1998;8:390-401.
115. 1A receptor agonists in rodent models of focal and global cerebral ischemia. Eur J Pharmacol 1991;203:213-222.
116. Raiteri M, Maura G, Barzizza A. Activation of presynaptic 5-hydroxytryptamine1-like receptors on glutamatergic terminals inhibits N-methyl-D-aspartate-induced cyclic GMP production in cerebellar slices. J Pharmacol Exp Ther 1991;257:1184-1188.
117. 1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization. Brain Res 2004;1030:201-220.
118. Ringelstein EB, Biniek R, Weiller C, Ammeling B, Nolte PN, Thron A. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 1992;42:289-298.
119. Rothoerl RD, Woertgen C, Brawanski A. S-100 serum levels and outcome after severe head injury. Acta Neurochir 2000;Suppl 76:97-100.
120. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105-111.
121. 1A receptor agonists on glutamate induced rise in cytosolic calcium concentration as well as on calcium and potassium currents in hippocampal neurons. In: Pharmacology of cerebral ischemia, Krieglstein J, Oberpichler-Schwenk H, Ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1994;89-94.
122. Sacco RL. Frequency and determinants of stroke. In: Clinical Atlas of Cerebrovascular Disease, Fisher M, Ed. London: Mosby-Year Book Europe, 1994;1.1-1.16.
123. 1A receptors reduces apoptosis after transient forebrain ischemia in the rat. Brain Res 2000;883:41-50.
124. Schurr A. Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels. Curr Drug Targets 2004;5:603-618.
125. Schwartz JP, Mishler K. Beta-adrenergic receptor regulation through cyclic AMP, of nerve growth factor expression in rat cortical and cerebellar astrocytes. Cell Mol Neurobiol 1990;10:447-457.
126. 1A neuro-protectant BAY x 3702 in the rat. Soc Neurosci Abstr 1997;23:1923(Abstract 745.7)
127. Schwarz T, Beckermann B, Buehner K, et al. Pharmacokinetics of repinotan in healthy and brain injured animals. Biopharm Drug Dispos 2005;26:259-268.
128. Semkova I, Schilling M, Henrich-Noack P, Rami A, Krieglstein J. Clenbuterol protects mouse cerebral cortex and rat hippocampus from ischemic damage and attenuates glutamate neurotoxicity in cultured hippocampal neurons by induction of NGF. Brain Res 1996;717:44-54.
129. 1A receptor agonist Bay x 3702 demonstrated in vitro and in vivo. Eur J Pharmacol 1998;359:251-260.
130. Shapira Y, Yadid G, Cotev S, Niska A, Shohami E. Protective effect of MK-801 in experimental brain injury. J Neurotrauma 1990;7:131-139.
131. 2 receptor agonists. Eur J Pharmacol 1992;229:21-29.
132. Shimizu H, Graham SH, Chang LH, et al. Relationship between extracellular neurotransmitter amino acids and energy metabolism during cerebral ischemia in rats monitored by microdialysis and in vivo magnetic resonance spectroscopy. Brain Res 1993;605:33-42.
133. Siesjö BK. Pathophysiology and treatment of focal cerebral ischemia, Part II: Mechanisms of damage and treatment. J Neurosurg 1992;77:337-354.
134. Srkalovic G, Selim M, Rea MA, Glass JD. Serotonergic inhibition of extracellular glutamate in the suprachiasmatic nuclear region assessed using in vivo brain microdialysis. Brain Res 1994;656:302-308.
135. Stuiver BT, Douma BRK, Bakker R, Nyakas C, Luiten PGM. In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: Combined therapy and temporal course of protection. Neurodegeneration 1996;5:153-159.
136. 1A receptor agonist BAY x 3702 prevents staurosporine-induced apoptosis. Eur J Pharmacol 1998;355:95-101.
137. 2+ channels. J Neurosci 1999;19:890-899.
138. Ueda S, Hou XP, Whitaker-Azmitia PM, Azmitia EC. Neuro-glial neurotrophic interaction in the S-100β retarded mutant mouse (Polydactyly Nagoya): II, Co-cultures study. Brain Res 1994;633:284-288.
139. 1A subtype. Eur J Pharmacol 1985;113:463-464.
140. Whitaker-Azmitia PM, Azmitia EC. Autoregulation of fetal serotonergic neuronal development: Role of high-affinity serotonin receptors. Neurosci Lett 1986;67:307-311.
141. 1A receptors and S-100β in development and plasticity. Perspect Dev Neurobiol 1994;2:233-238.
142. 1A receptors. Brain Res 1990;528:155-158.
143. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg MS. Opposing effects on ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-1331.
144. 1A receptors mediate neurotrophic effect of serotonin on developing dentate granule cells. Dev Brain Res 1995;98:185-190.
145. Yan HQ, Yu J, Kline AE, et al. Evaluation of combined fibroblast growth factor-2 and moderate hypothermia therapy in traumatically brain injured rats. Brain Res 2000;887:136-145.
146. Yenari MA, Bell TE, Kotake AN, Powell M, Steinberg GK. Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients. Clin Neuropharmacol 1998;21:28-34.
147. Zafra F, Lindholm D, Castren E, Hartikka J, Thoenen H. Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes. J Neurosci 1992;12:4793-4799.
148. Zhou FC, Azmitia EC, Bledsoe S. Rapid serotonergic fiber sprouting in response to ibotenic acid lesion in the striatum and hippocampus. Dev Brain Res 1995;84:89-98.